Evidence map›Paper›PMID 28361235›Full record

Trial reportClinical rheumatology2017

DASH diet and change in serum uric acid over time.

Olive Tang, Edgar R Miller, Allan C Gelber, Hyon K Choi, Lawrence J Appel, Stephen P Juraschek

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Olive TangJohns Hopkins University School of Medicine, Baltimore, USA.
Edgar R MillerJohns Hopkins University School of Medicine, Baltimore, USA.
Allan C GelberJohns Hopkins University School of Medicine, Baltimore, USA.
Hyon K ChoiHarvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
Lawrence J AppelJohns Hopkins University School of Medicine, Baltimore, USA.
Stephen P JuraschekJohns Hopkins University School of Medicine, Baltimore, USA. spj@jhmi.edu.

Funding

Zoledronic Acid in Treatment of Osteoporosis in PostmenoM01RR002635 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · PI WILLIAMS, GORDON H · 1985 to 2008
$48.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
RENAL DISEASE EPIDEMIOLOGY TRAINING GRANTT32DK007732 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CREWS, DEIDRA CANDICE · 1995 to 2024
$7.7M
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUTR01AR065944 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HYON K · 2013 to 2025
$4.2M
Vitamin D, Subclinical Cardiovascular Disease, and Orthostatic Hypotension in Older AdultsK23HL135273 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JURASCHEK, STEPHEN P · 2017 to 2021
$1.1M
DIETARY PATTERNS, SODIUM INTAKE, AND BLOOD PRESSUREU01HL057114 · NHLBI · DUKE UNIVERSITY · PI SVETKEY, LAURA P · 1997 to 2000
$159k
ZIDOVUDINE WITH PROBENECID--EFFECTS OF PROBENECID ON ZIDOVUDINEM01RR000722 · NCRR · JOHNS HOPKINS UNIVERSITY · 1985 to 1996
–
NCRR NIH HHS M01 RR000722NCRR NIH HHS M01 RR002635NHLBI NIH HHS K23 HL135273NHLBI NIH HHS U01 HL057114NIAMS NIH HHS R01 AR065944NIA NIH HHS L30 AG051250NIDDK NIH HHS T32 DK007732NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

The Dietary Approaches to Stop Hypertension (DASH) diet lowers serum uric acid (SUA) levels compared to the typical American (control) diet. However, the time required for the DASH diet to take effect is unknown. We analyzed data from a parallel arm, randomized-controlled trial in pre-hypertensive or hypertensive adults (N = 103), comparing the effects of DASH or a control diet on SUA measured at 30, 60, and 90 days. Effects were examined overall and within stratified subgroups based on baseline SUA status (SUA ≥6 mg/dL vs <6 mg/dL). The mean age of participants was 51.5 ± 9.7 years, 55% were women, 75% were black, 42% were obese, and 34% had hypertension. Twenty-four of the 103 (23%) participants had a baseline SUA ≥6 mg/dL. Overall, compared to the control, DASH lowered SUA by 0.5 mg/dL at 30 and 90 days. Among participants with baseline SUA ≥6 mg/dL, DASH lowered SUA by 0.8 and 1.0 mg/dL at 30 and 90 days, respectively. These findings demonstrate that the DASH diet reduces SUA within 30 days, with a sustained effect at 90 days, which is informative for healthcare providers counseling patients on time course expectations for uric acid reduction in response to dietary modification.

Indexed as

Dietary Approaches To Stop HypertensionAdultFemaleHumansHypertensionMaleMiddle AgedUric AcidUric AcidDASHDietGoutTrialUric acid

Identifiers

PMID28361235
PMCPMC5821061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.